Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Seeks Chronic Hives Indication for Xolair
June 20, 2016
- Aspen Japan Looks to Expand Biz through Essential Drugs, AGs: President
June 20, 2016
- Jardiance Reduces Kidney Disease Risks Too, by 39%
June 17, 2016
- Eisai to Book 9.2 Billion Yen Gain from EA Pharma Share Acquisition
June 17, 2016
- AnGes MG to License Oral CIN Therapeutic Vaccine to Morishita Jintan
June 17, 2016
- PeptiDream’s Macrocyclic Compound Advances to Clinical Stage
June 16, 2016
- Seikagaku Licenses Lumbar Disc Herniation Drug to Ferring
June 16, 2016
- Selexipag Reaches European Soil, Now Available in Germany: Nippon Shinyaku
June 16, 2016
- Novartis Japan to Revamp Ophthalmology Drug Biz amid Global Drive
June 16, 2016
- Roche to Top Global Drug Maker Ranking in 2020, Consulting Firm Predicts
June 16, 2016
- Merck Serono Can Catch Up with Rivals in Immuno-Oncology Space: Japan Oncology Head
June 16, 2016
- Eisai’s Anti-Fractalkine Antibody Suggests Safety in RA
June 15, 2016
- Sawai to Make 700 Factory Contractors Permanent Employees
June 15, 2016
- SymBio Kicks Off Japan PIII for Patient-Controlled Pain Management Drug
June 15, 2016
- PDUFA Date Set for Jan. 31, 2017 for Daiichi Sankyo’s Nausea Drug
June 15, 2016
- Otsuka, Acucela End Partnership on AMD Drug after Trial Data Disappoint
June 15, 2016
- Ethical Drug Sales Up 8.1% in April: Crecon Report
June 14, 2016
- No Higher Mortality Risk Including CV Death Observed with Alogliptin against Placebo: Takeda
June 14, 2016
- Dave Fredrickson Tapped as Next Chief of AstraZeneca Japan
June 13, 2016
- Takeda Looks to Join Top 10 List in Global Oncology Space in 2025
June 10, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…